Citations

Showing 10 of 108094 citations.

Progressive motor impairment from “critical” demyelinating lesions of the cervicomedullary junction
Jackson-Tarlton, Caitlin S. , Barakat, Benan , Ahmad, Rowaid, Kantarci, Orhun H. , Keegan, B. Mark , Flanagan, E P , Messina, Steven Anthony, Barakat, Benan , Keegan, B Mark , Flanagan, Eoin P. , Messina, Steven A. , Ahmad, Rowaid, Weinshenker, Brian G.

Mayo Clinic

Multiple Sclerosis Journal | August 24, 2022 | Volume: 29 | Issue: 1 | Pages: 74-80

10.1177/13524585221114438 | PMID 36000479 Get It

Background: Progressive motor impairment anatomically associated with a “critical” lesion has been described in primary demyelinating disease. Most “critical” lesions occur within the spinal cord. Objective: To describe the clinical and radiological features of “critical” lesions of the cervicomedullary junction (CMJ). Methods: Observational study on people presenting with a CMJ lesion associated with primary demyelinating disease-related progressive motor impairment. Clinical data were extracted by chart review. Brain and spinal cord magnetic resonance images were reviewed to characterize the CMJ lesion and determine additional demyelination burden. Results: Forty-one people were included: 29 (71%) had progression from onset and 12 (29%) had a relapse onset (secondary progressive) course. Most had progressive hemiparesis (21 (51%)) or progressive quadriparesis (15 (37%)) with a median Expanded Disability Status Scale (EDSS) of 5.5 (2.0–8.5) at last follow-up. No “critical” CMJ lesion enhanced; most were bilateral (25 (61%)). Brain magnetic resonance images were otherwise normal in 16 (39%) or with a restricted demyelination burden in 15 (37%). Cervical and thoracic cord MRIs were without additional lesions in 25 (61%) and 22/37 (59%), respectively. Conclusion: CMJ “critical” lesions can correlate with progressive motor impairment even with few or no additional magnetic resonance imaging (MRI) lesions. Lesion location is an important determinant of progressive motor impairment in demyelinating disease.
Priapism or Prolonged Erection: Is 4 – 6 Hours of Cavernous Ischemia the Time Point of Irreversible Tissue Injury?
Dekalo, Snir , Stern, Noah , Brock, Gerald, Broderick, Gregory A.

Mayo Clinic

Sexual Medicine Reviews | August 24, 2022 | Volume: 10 | Issue: 4 | Pages: 660-668

10.1016/j.sxmr.2022.06.007 | PMID 36028433 Get It

Abstract Introduction Ischemic priapism remains a significant cause of morbidity among men. To date, the precise time when penile ischemia results in permanent, non-reversible cavernosal smooth muscle injury, compromising subsequent erectile integrity, remains ill-defined. Objectives To review the medical literature pertaining to ischemic priapism, focusing on factors that predict the exact timeline of irreversible cavernous tissue injury. Methods A comprehensive literature search was performed. Our search included both publications on animal models and retrospective clinical series through January 2022. Articles were eligible for inclusion if they contained original data regarding nonreversible tissue injury on histology and/or provided a timeline of erectile function loss or preservation and had full text available in English. Results Innovative studies in the 1990s using invitro models with strips of rabbit, rat, canine and monkey corpus cavernosal tissue demonstrated that anoxia eliminated spontaneous contractile activity and reduced tissue responsiveness to electrical field stimulation or pharmacological agents. The same models demonstrated that the inhibitory effects of field stimulated relaxation, were mediated by nitric oxide. Subsequent studies using similar models demonstrated that exposure of corpus cavernosum smooth muscle to an acidotic environment impairs its ability to contract. A pH of 6.9 was chosen for these experiments based on a case series of men with priapism, in whom a mean pH of 6.9 was measured in corporal blood after 4–6 hours of priapism. Invivo animal studies demonstrated that after erection periods of 6–8 hours, microscopy shows sporadic endothelial defects but otherwise normal cavernous smooth muscle. In these studies, greater durations of ischemic priapism were shown to result in more pronounced ultrastructural changes and presumably irreversibility. In studies involving human corporal tissues, samples were obtained from men who had experienced priapism for at least 12 hours. Overall, erectile function outcome data is deficient in priapism reporting, especially within treatment windows less than 6 hours. Some reports on ischemic priapism have documented good erectile function outcomes with reversal by 12 hours. Conclusion Based on our extensive review of animal models and clinical reports, we found that many clinical papers rely on the same small set of animal studies to suggest the time point of irreversible ischemic damage at 4–6 hours. Our review suggests an equal number of retrospective clinical studies demonstrate that ischemic priapism reversed within 6–12 hours may preserve erectile function in many patients.
Assessment of Knowledge Regarding Risks and Benefits of the Use of Non-Vitamin K Antagonist Oral Anticoagulants
Valery, Jose R. , Marar, Ahmad, Ward, Cynthia R. , Abdelmoneim, Yousif , Fitzgerald, Patrick , Mwakyanjala, Edson J., Harris, Dana M. , Murray, Loren P., White, Launia J. , Valery, Jose , Ward, Cynthia, Abdelmoneim, Yousif M, Fitzgerald, Patrick J, Mwakyanjala, Edson, Harris, Dana M , Murray, Loren, Stancampiano, Fernando F , Pujalte, George , Ward, Cynthia, Heckman, Michael G. , Stancampiano, Fernando F.

Mayo Clinic

Journal of Primary Care & Community Health | August 24, 2022 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/21501319221118806 | PMID 36000450 Get It

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have replaced vitamin K antagonist (VKA) oral anticoagulants as the first-line treatment option for stroke prevention in high-risk patients with atrial fibrillation. With VKA therapy, disease and treatment-related knowledge is associated with improved adherence and outcomes. There is concern that due to the lack of need for ongoing visits for laboratory monitoring in patients on NOACs, there is less opportunity for education, leading to poor disease- and treatment-related knowledge in this patient group. Methods: One hundred ninety-nine (199) patients presenting to 2 primary care clinics on NOAC therapy were surveyed regarding atrial fibrillation and their knowledge regarding NOACs. Chart review was completed to determine patient characteristics and data obtained was compared with survey results to determine the accuracy of the survey responses. Results: Patients with a lower degree of NOAC knowledge tended to be older ( P < .001), have higher Charlson Comorbidity Index scores ( P = .001), use apixaban more often ( P = .008), and have been on NOACs for a shorter time period ( P = .007). Conclusions: There is an opportunity to improve NOAC-related knowledge in patients with atrial fibrillation. When developing educational interventions, patient characteristics associated with poor knowledge should be considered. Based on our results, these are patients who are older, more medically complex, are on apixaban, and have been on NOAC therapy for a shorter duration.
Religiosity/Spirituality and Cardiovascular Health: The American Heart Association Life's Simple 7 in African Americans of the Jackson Heart Study
Brewer, LaPrincess C. , Bowie, Janice , Slusser, Joshua P. , Scott, Christopher G. , Hayes, Sharonne N. , Sims, Mario , Hayes, Sharonne N , Patten, Christi A. , Scott, Christopher , Brewer, LaPrincess C , Cooper, Lisa A.

Mayo Clinic

Journal of the American Heart Association | August 24, 2022 | Volume: 11 | Issue: 17 | Pages: No page available

10.1161/jaha.121.024974 | PMID 36000432 Get It

Background Religiosity/spirituality is a major coping mechanism for African Americans, but no prior studies have analyzed its association with the American Heart Association Life's Simple 7 (LS7) indicators in this group. Methods and Results This cross‐sectional study using Jackson Heart Study (JHS) data examined relationships between religiosity (religious attendance, private prayer, religious coping) and spirituality (theistic, nontheistic, total) with LS7 individual components (eg, physical activity, diet, smoking, blood pressure) and composite score among African Americans. Multivariable logistic regression assessed the odds of achieving intermediate/ideal (versus poor) LS7 levels adjusted for sociodemographic, behavioral, and biomedical factors. Among the 2967 participants (mean [SD] age=54.0 [12.3] years; 65.7% women), higher religious attendance was associated with increased likelihood (reported as odds ratio [95% CI]) of achieving intermediate/ideal levels of physical activity (1.16 [1.06–1.26]), diet (1.10 [1.01–1.20]), smoking (1.50 [1.34–1.68]), blood pressure (1.12 [1.01–1.24]), and LS7 composite score (1.15 [1.06–1.26]). Private prayer was associated with increased odds of achieving intermediate/ideal levels for diet (1.12 [1.03–1.22]) and smoking (1.24 [1.12–1.39]). Religious coping was associated with increased odds of achieving intermediate/ideal levels of physical activity (1.18 [1.08–1.28]), diet (1.10 [1.01–1.20]), smoking (1.32 [1.18–1.48]), and LS7 composite score (1.14 [1.04–1.24]). Total spirituality was associated with increased odds of achieving intermediate/ideal levels of physical activity (1.11 [1.02–1.21]) and smoking (1.36 [1.21–1.53]). Conclusions Higher levels of religiosity/spirituality were associated with intermediate/ideal cardiovascular health across multiple LS7 indicators. Reinforcement of religiosity/spirituality in lifestyle interventions may decrease overall cardiovascular disease risk among African Americans.
Influence of β 1 Adrenergic Receptor Genotype on Longitudinal Measures of Left Ventricular Ejection Fraction and Responsiveness to ß-Blocker Therapy in Patients With Duchenne Muscular Dystrophy
Kelley, Eli F. , Cross, Troy J. , Investigators, CINRG, Hoffman, Eric P. , Spurney, Christopher F. , Bello, Luca , Cross, Troy James , McDonald, Craig M

Mayo Clinic

Clinical Medicine Insights: Cardiology | August 24, 2022 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/11795468221116838 | PMID 36046180 Get It

The purpose of this study was to determine whether the longitudinal progression of decline in left ventricular ejection fraction (LVEF) in Duchenne muscular dystrophy (DMD) patients is moderated by ADRB1 genotype and whether the efficacy of ß-blocker therapy is influenced by genotype status. About 147 DMD patients (6-34 years.) were analyzed with a focus on β 1 adrenergic receptor (ADRB1) genotype variants. Patients were grouped by ADRB1 genotype resulting in Gly389 patients and Arg389 patients. A generalized additive mixed effects model was used to examine differences in the nonlinear trend of LVEF across patient ages between genotype groups and for ß-blocker use. Both genotype groups displayed a progressive decline in LVEF starting around the mean age of ambulation loss (~12 years). However, there was no difference between genotype groups in the progression of decline in LVEF. There was a significant effect of ß-blocker use on longitudinal LVEF, wherein patients on ß-blockers had systematically lower LVEF when compared to patients not on ß-blockers. However, the effect of ß-blocker therapy on LVEF was not affected by ADRB1 genotype. The current study did not demonstrate an influence of patient ADRB1 genotype on longitudinal LVEF in our cohort. Despite previous literature suggesting a positive influence of ß-blocker use on cardiac function in DMD patients and of an ADRB1 genotypic difference in responsiveness to ß-blocker use, we did not observe this in our cohort. Interestingly, our cohort did not demonstrate a positive influence of ß-blocker use on LVEF measures.
Assessing intrinsic renal sodium avidity in acute heart failure: implications in predicting and guiding decongestion
Chen, Horng H. , Testani, Jeffrey, Müllens, Wilfried , Verbrugge, Frederik H. , Tang, W.H. Wilson

Mayo Clinic

European Journal of Heart Failure | August 23, 2022 | Volume: 24 | Issue: 10 | Pages: 1978-1987

10.1002/ejhf.2662 | PMID 36054180 Get It

ABSTRACT Aim Intrinsic renal sodium avidity (IRSA) is a hallmark feature of acute heart failure (AHF) and can be measured by evaluating the urinary sodium (UNa) concentration. The aim of this study is to assess the role of measuring IRSA through a random Una‐sample and its association with decongestive response. Methods and results A post‐hoc analysis of the ROSE‐AHF trial was performed in all patients with a random UNa spot sample before randomization ( n = 339/360). Patients were categorized according to tertiles of UNa as high (range 19–40 mmol/L), intermediate (range 41–68 mmol/L), or low (range 69–139 mmol/L) IRSA. Linear mixed effect models and ANCOVA were used to assess the relation with decongestive effectiveness measured by: (i) weight change, (ii) visual analogue scale (VAS) improvement, (iii) N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) change, (iv) natriuretic response (UNa in mmol/L), (v) 72 h natriuresis (mmol), (vi) oedema resolution, and (vii) length of stay. High IRSA patients had less improvement in decongestive metrics, including weight loss ( p = 0.028), VAS improvement, NT‐proBNP decrease, natriuretic response ( p ‐time interaction <0.001 for all), had lower total natriuresis (high IRSA 438 ± 141 mmol, intermediate IRSA 526 ± 320 mmol, and low IRSA 603 ± 276 mmol; p < 0.001), exhibited more oedema at 72 h ( p = 0.005), and had a longer length of stay ( p = 0.015). Incremental loop diuretic dose titration (± 4 times home dose) after >24 h, resulted in an increase in natriuretic response in the high IRSA group, however cumulative natriuresis still remained lower at 72 h ( p < 0.001). Longitudinal UNa profiling of patients with low IRSA showed physiologic breaking in the UNa pattern, associated with attaining decongestion and slight increase in creatinine and cystatin C, forming a potential signal of complete decongestion. Conclusions A simple random UNa sample at the time of AHF, gives insight into IRSA which is consistently associated with decongestive effectiveness across multiple metrics, offering an opportunity for early AHF care improvement.
Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies
Kanack, Adam J. , Jones, Curtis G., Singh, Bandana, Leger, Rachel, Splinter, Noah P., Heikal, Nahla, Pruthi, Rajiv K. , Chen, Dong , George, Gemlyn , Gundabolu, Krishna , Padmanabhan, Anand , Leger, Rachel R, Heikal, Nahla M, Abou-Ismail, Mouhamed Yazan , Wool, Geoffrey , Gundabolu, Krishna , Padmanabhan, Anand , Chen, Dong , Wool, Geoffrey D.

Mayo Clinic

Blood | August 23, 2022 | Volume: 140 | Issue: 25 | Pages: 2722-2729

10.1182/blood.2022017283 | PMID 35998675 Get It

AbstractHeparin-induced thrombocytopenia (HIT) is suspected much more often than it is confirmed. Technically simple platelet factor 4 (PF4)-polyanion enzyme-linked immunosorbent assays (ELISAs) are sensitive but nonspecific. In contrast, accurate functional tests such as the serotonin release assay, heparin-induced platelet activation assay, and PF4-dependent P-selectin expression assay require fresh platelets and have complex assay end points, limiting their availability to specialized reference laboratories. To enable broad deployment of functional testing, we sought to extend platelet viability significantly by optimizing storage conditions and developed a simple functional assay end point by measuring the release of a platelet α-granule protein, thrombospondin-1 (TSP1), in an ELISA format. Platelet cryopreservation conditions were optimized by freezing platelets at controlled cooling rates that preserve activatability. Several-month-old cryopreserved platelets were treated with PF4 or heparin and were evaluated for their ability to be activated by HIT and vaccine-induced immune thrombotic thrombocytopenia (VITT) antibodies in the TSP1 release assay (TRA). HIT and spontaneous HIT patient samples induced significantly higher TSP1 release using both PF4-treated (PF4-TRA) and heparin-treated cryopreserved platelets relative to samples from patients suspected of HIT who lacked platelet-activating antibodies. This latter group included several patients that tested strongly positive in PF4-polyanion ELISA but were not platelet-activating. Four VITT patient samples tested in the TRA activated PF4-treated, but not heparin-treated, cryopreserved platelets, consistent with recent data suggesting the requirement for PF4-treated platelets for VITT antibody detection. These findings have the potential to transform the testing paradigm in HIT and VITT, making decentralized, technically simple functional testing available for rapid and accurate in-hospital diagnosis.
Real-time Ultrasound-Guided Manual Testicular Detorsion: A Case Report
Smith, W. Ted, Midgley, S.J.E. , Kummer, Tobias , Midgley, Stephanie

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | August 23, 2022 | Volume: 6 | Issue: 3 | Pages: 248-251

10.5811/cpcem2022.6.57256 | PMID 36049193 Get It

Introduction: Acute testicular torsion is a surgical emergency due to acute testicular ischemia. Manual testicular detorsion is a testis-saving, bedside therapeutic when performed correctly and in a timely fashion. This procedure is most commonly performed blindly with pain relief as the endpoint for detorsion. However, up to one-third of patients continued to show signs of residual torsion in the operating room even using pain relief as the stopping point for the procedure. Case Report: We present a case demonstrating the utility of color Doppler ultrasound to confirm complete manual detorsion in a 14-year-old male with acute testicular torsion. The patient underwent 360-degree detorsion and had relief of pain; however, color Doppler demonstrated incomplete return of flow to the testis. After an additional 180-degree turn was made, color Doppler demonstrated complete return of normal vascular flow to the torsed testis. Conclusion: When it comes to testicular viability, timely restoration of blood flow to the testicle is of utmost importance. Manual detorsion is a non-invasive intervention that can be quickly and effectively performed at the bedside. Moreover, using color Doppler ultrasound guidance can ensure that physicians detorse in the proper direction and to completion, by providing instant visualization of restorative flow and ensuring reperfusion of the testis while awaiting definitive surgical management.
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing
Ibarra, Manuel , Taylor, Zachary L. , Ramsey, Laura B. , Mikkelsen, Torben Stamm , Barreto, Jason N. , Guscott, Martin , Lowe, Jennifer K. , Hurmiz, Charles, Marada, Suresh, Schaiquevich, Paula S. , Combs, Ryan, Buddington, Randal K. , Heldrup, Jesper , Lowe, Jennifer, Howard, Scott C.

Mayo Clinic

British Journal of Clinical Pharmacology | August 23, 2022 | Volume: 89 | Issue: 2 | Pages: 660-671

10.1111/bcp.15506 | PMID 35998099 Get It

AimsHigh‐dose methotrexate (HDMTX) is an essential part of the treatment of several adult and paediatric malignancies. Despite meticulous supportive care during HDMTX administration, severe toxicities, including acute kidney injury (AKI), may occur contributing to patient morbidity. Population pharmacokinetics provide a powerful tool to predict time to clear HDMTX and adjust subsequent doses. We sought to develop and validate pharmacokinetic models for HDMTX in adults with diverse malignancies and to relate systemic exposure with the occurrence of severe toxicity.MethodsAnonymized, de‐identified data were provided from 101 US oncology practices that participate in the Guardian Research Network, a non‐profit clinical research consortium. Modelled variables included clinical, laboratory, demographic and pharmacological data. Population pharmacokinetic analysis was performed by means of nonlinear mixed effects modelling using MonolixSuite.ResultsA total of 693 HDMTX courses from 243 adults were analysed, of which 62 courses (8.8%) were associated with stage 2/3 acute kidney injury (43 stage 2, 19 stage 3). A three‐compartment model adequately fitted the data. Time‐dependent serum creatinine, baseline serum albumin and allometrically scaled bodyweight were clinically significant covariates related to methotrexate clearance. External evaluation confirmed a satisfactory predictive performance of the model in adults receiving HDMTX. Dose‐normalized methotrexate concentration at 24 and 48 hours correlated with AKI incidence.ConclusionWe developed a population pharmacometric model that considers weight, albumin and time‐dependent creatinine that can be used to guide supportive care in adult patients with delayed HDMTX elimination.
Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
Li, Dalin , Debbas, Philip , McGovern, Dermot , Melmed, Gil , Group, CORALE-IBD Study, Banty, Andrea, Feldman, Edward J., Ha, Christina , Lee, Susie, Rabizadeh, Shervin , Stein, Theodore , Solomon, Theodore, Syal, Gaurav , Targan, Stephan R. , Vasiliauskas, Eric, Ziring, David , Bonthala, Niru, Botwin, Gregory S, Hampton, Melissa, Khanishian, Elizabeth, Pozdnyakova, Valeriya , Gu, Phillip , White, Shane , Zamudio, Cindy, Gonzalez, Daniel , Parry, Alyssa, Hanna, Mary , Chan, Justin, Ebinger, Joe , Wu, Min , Hoang, Amy, Wynter, Timothy , Sun, Nancy , Figueiredo, Jane C. , Merchant, Akil , Merin, Noah , Appel, Keren , Boland, Brigid S. , Charabaty, Aline , Chiorean, Michael , Cohen, Erica , Flynn, Ann D. , Valentine, John F. , Ehrlich, Adam C., Fudman, David , Horizon, Arash, Karayev, Dmitry, Kretzmann, Benjamin, Hou, Jason K. , Hwang, Caroline, Lazarev, Mark , Lum, Donald , Fausel, Rebecca, Reddy, Swapna , McConnell, Ryan , Mattar, Mark , Metwally, Mark, Ostrov, Arthur, Parekh, Nimisha, Raffals, Laura H., Sheibani, Sarah , Younes, Ziad , Damas, Oriana M. , Braun, Jonathan , Melmed, Gil Y , Mujukian, Angela , Cheng, Susan , Group, CORALE-IBD Study, Botwin, Gregory J., Mengesha, Emebet , White, Shane, Joung, Sandy , Hoang, Amy, Reckamp, Karen L. , Kumar, Rashmi , Rubin, David T. , Siegel, Corey A , Wolf, Douglas C.

Mayo Clinic

Inflammatory Bowel Diseases | August 23, 2022 | Volume: 29 | Issue: 6 | Pages: 883-887

10.1093/ibd/izac174 | PMID 35998072 Get It

AbstractBackgroundThe safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.MethodsWe compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD.ResultsThe study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse.ConclusionThe frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.